Hormonal
Elevated serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are not merely biomarkers of liver injury but reflect active hepatic transamination and deregulated amino acid metabolism (specifically the glutamine-glutamate cycle) that contributes to the pathogenesis of metabolic syndrome and insulin resistance.
If your ALT or AST levels are elevated, even within the 'normal' lab range, do not dismiss them as normal. This paper suggests these enzymes are active participants in metabolic syndrome, driving insulin resistance through amino acid metabolism. You should view elevated liver enzymes as a warning sign of metabolic dysregulation and prioritize interventions that improve insulin sensitivity and liver health, such as reducing refined carbohydrate intake and managing body weight, rather than ignoring them because you feel fine.
We consider that the hypothesis about the role of abnormal glutamate metabolism in the pathogenesis of the MS is certainly challenging and suggests the critical role of the liver in the global metabolic modulation as glutamate metabolism is linked with aminotransferase reactions... postulates that before fatty liver develops, abnormal levels of liver enzymes, such as alanine and aspartate aminotransferases might reflect high levels of hepatic transamination of amino acids in the liver.
Why this rating
The paper is a review/commentary synthesizing observational cohort studies and animal models; it proposes a hypothesis rather than presenting new primary clinical trial data.
Source
Alanine and aspartate aminotransferase and glutamine-cycling pathway: Their roles in pathogenesis of metabolic syndrome
Silvia Sookoian · World Journal of Gastroenterology · 2012
DOI 10.3748/wjg.v18.i29.3775
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →